PROJECT STAGE
Therapeutic area
Alzheimer’s Disease
Background info
Indication
Advantages
Intellectual property
Owner/lead
Project Aim
To develop a humanised antibody that specifically targets toxic species of Aβ for Alzheimer’s Disease
Advantage
A novel approach to specifically target Aβ N-terminal oligomers
Target Class
Extracellular Protein
Modality
Antibody
Current Status
Lead with in-vivo proof of concept
Intellectual Property
Existing patent applications with scope for additional IP protection
Offering
Licence or collaboration for preclinical / clinical development